Latest Merck Research Laboratories Stories
As well as results from its Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Showing High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus
Pembrolizumab Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer First Findings from KEYNOTE-028, Merck's Innovative
Data from KEYNOTE-006 Study Presented at AACR Annual Meeting and Published in the New England Journal of Medicine KIRKLAND, QC, April 19, 2015 /CNW Telbec/ - Merck (NYSE: MRK),
KIRKLAND, QC, April 19, 2015 /CNW Telbec/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating pembrolizumab,
KENILWORTH, N.J., Feb.
SITC-Merck Cancer Immunotherapy Clinical Fellowship Award to Grant Young Investigator $100,000 to Advance the Field Milwaukee, WI (PRWEB) January 26, 2015
CAMBRIDGE, Mass., Jan.
Overall Response Rate of 66 Percent Observed in Pembrolizumab-treated Patients Whose Cancer Progressed on Brentuximab Vedotin Phase 2 Study Planned for the First Half of 2015
Agreement to fund development of compounds for cognitive impairment associated with Alzheimer's disease and other conditions of the central nervous system SAN DIEGO,
CAMBRIDGE, Mass., June 2, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings
- A serpent whose bite was fabled to produce intense thirst.